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Abstract
Background: Pattern recognition receptors (PRRs) such as Toll-like receptors are aberrantly expressed of peripheral blood
mononuclear cells (PBMCs) in systemic lupus erythematosus (SLE) patients, for playing immunopathological roles.
Methodology/Principal Findings: We investigated the expression and function of the PRR nucleotide-binding
oligomerization domain (NOD2) in SLE. NOD2 expression in T, B lymphocytes, monocytes, myeloid dendritic cells (mDCs)
and plasmacytoid dendritic cells (pDCs) was assessed in SLE patients and healthy controls (HCs) using flow cytometric
analysis. Ex vivo production of cytokines from PBMCs upon NOD2 agonist muramyl dipeptide (MDP) stimulation was
assessed using Cytometric Bead Array. Over-expression of NOD2 in monocytes was observed in immunosuppressant naı ¨ve
SLE patients, and was positively associated with longer disease duration. Immunosuppressive therapy was an independent
explanatory variable for downregulating NOD2 expression in CD8+ T, monocytes, mDCs and pDCs. Ex vivo basal productions
of cytokines (IL-6, IL-8 and IL-10) were significantly increased in immunosuppressant naı ¨ve patients and patients with active
disease despite immunosuppressants compared with HCs. Upon MDP stimulaiton, relative induction (%) of cytokines (IL-1b)
from PBMC was significantly increased in immunosuppressant naı ¨ve patients with inactive disease, and patients with active
disease despite immunosuppressant treatment compared with HCs. Immunosuppressant usage was associated with a
decreased basal production and MDP induced relative induction (%) of IL-10 in patients with inactive disease compared
with immunosuppressant naı ¨ve patients and HCs.
Conclusions/Significance: Bacterial exposure may increase the NOD2 expression in monocytes in immunosuppressant
naı ¨ve SLE patients which can subsequently lead to aberrant activation of PBMCs to produce proinflammatory cytokines,
implicating the innate immune response for extracellular pathogens in the immunopathological mechanisms in SLE.
Immunosuppressant therapy may downregulate NOD2 expression in CD8+ T lymphocytes, monocytes, and DCs in SLE
patients which subsequently IL-10 reduction, contributing towards the regulation of immunopathological mechanisms of
SLE, at the expense of increasing risk of bacterial infection.
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Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease
with unknown etiology affecting more than one million individuals
each year. It is characterized by B and T cell hyperactivity, and
defects in the clearance of apoptotic cells and immune complexes
[1]. Besides genetic factors, environmental triggers can also
contribute to pathogenesis of SLE. An infectious etiology of SLE
has been longstanding hypothesis [2,3,4] and with the discovery of
pattern recognition receptors (PRRs) in SLE patients, the role of
bacteria and viruses in the pathogenesis of SLE has been
invigorated.
PRRs can alert and activate the innate immune system through
recognizing the conserved molecular patterns to distinguish
extrinsic pathogen-associated molecular patterns (PAMPs) and
endogenous danger-associated molecular patterns (DAMPs). PRRs
were involved in the development of various inflammatory
disorders [5]. The activation of PRR-mediated proinflammatory
cascades leads to the clearance of invading pathogen, and the
subsequent resolution of inflammation [6]. Along with the
identification of endogenous ligands for many PRRs, PRRs might
also respond to damaged tissue and apoptotic cell debris [6].
Furthermore, activation of PRRs has been found to modulate
adaptive immune responses through the regulation of co-
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stimulation of B cells [7,8]. Being the most studied PRRs, toll-like
receptors (TLRs) mediated intracellular signaling is a crucial link
between innate and adaptive immunity [9]. Peripheral blood
mononuclear cells (PBMCs) of SLE patients with a higher
expression of TLRs are more prone to be activated by diverse
TLR ligands when compared with HCs [7,10]. Signaling through
MyD88- and Toll-IL-1 receptor-domain-containing adapter-
inducing interferon-b (TRIF)-dependent pathways results in the
activation of type I interferons (IFN)s, resulting in inflammation
and subsequent tissue damage in SLE [7,10,11].
In contrast to the well elucidated membrane-bound TLRs,
cytoplasmic nucleotide binding oligomerisation domain (NOD)
receptors are a new family of PRRs for the recognition of
extracellular PAMPs [12,13]. Two NOD-like receptor (NLR)
proteins, namely NOD1 and NOD2, can participate in the
signaling events triggered by host recognition of specific motifs of
bacterial peptidoglycans (PGNs) and, upon activation, induce the
production of proinflammatory mediators [12]. NOD1 recognizes
products from gram-negative bacteria (diaminopimelic acids),
whereas NOD2 senses muramyl dipeptide (MDP), a peptidoglycan
derived peptide from gram-negative as well as gram-positive
bacteria [14]. It has been shown that NLRs complement and
synergize with TLRs in innate immune responses [5,6,15,16].
NLRs are associated with inflammatory bowel disease such as
Crohn’s disease (CD) [17]. However, the precise mechanisms by
which NOD-mediated recognition of PGNs in the pathogenesis of
inflammatory diseases are still unclear. Possible pathogenic
mechanisms in rheumatoid arthritis (RA) patients and murine
experimental models included [6,16] (1) NOD2 functions to
induce proinflammatory effects in the inflamed joint, whereas
NOD1 has mainly an inhibitory role, exemplified by the inhibition
of cytokine production and decrease in cell influx in a model of
streptococcal cell wall (SCW)-induced arthritis; (2) NOD2 act
synergistically with TLR in the production of proinflammatory
and destructive mediators in RA patients. A better understanding
of the intracellular events induced by the interaction between
NLR and PGNs is therefore crucial for the elucidation of the
mechanisms of both the recognition of pathogens by the innate
immune system and the pathogenesis of chronic inflammation.
Apart from the putative link between genetic mutations of
NOD2 and SLE [18,19,20,21,22,23], little is known regarding the
expression and function of NOD2 in SLE. Therefore, in this cross-
sectional study, we investigated the role of NOD2 in the peripheral
antigen presenting cells (APCs), T, B lymphocytes, as well as the
role of NOD2 in the modulation of proinflammatory cytokines
induced by NOD2 ligand MDP of SLE patients and control
subjects.
Methods
SLE patients, control subjects, and blood samples
Forty-seven SLE patients of Southern Chinese origin were
recruited at the Rheumatology Out-Patient Clinic of the Prince of
Wales Hospital, the Chinese University of Hong Kong. Diagnosis
of SLE was established according to the 1997 American College of
Rheumatology (ACR) revised criteria for the classification of
SLE.[24] Patients were excluded from the study if they had prior
treatment with a monoclonal antibody or other biologic agents.
SLE patients were divided into 3 groups according to disease
activity as reflected by the systemic lupus erythematosus disease
activity index (SLEDAI) [25] and the use of immunosuppressants
as list below: Group 1) Patients with inactive disease (SLEDAI ,4)
who were never treated with immunosuppressants since the
diagnosis or within the past 10 years, whichever longer; Group 2)
Patients with inactive disease (SLEDAI ,4) who had received or
are currently on immunosuppressants; Group 3) Patients with
active disease (SLEDAI .4) who had received or are currently on
immunosuppressants. Thirty-one age- and sex-matched healthy
Chinese volunteers were recruited as controls (HC group). Twelve
mls of ethylenediamine tetra-acetic acid (EDTA) venous periph-
eral blood were collected from each patient and control.
Ethics approval has been obtained from Ethics Committee of
The Chinese University of Hong Kong-New Territories Ease
Cluster Hospitals, and informed consent was obtained from all
participants according to the Declaration of Helsinki.
Clinical and laboratory parameters
Patient information with regard to demographic characteristics,
clinical features, serological profile and medications were retrieved
from medical records. Physical examinations and laboratory
investigations including complete blood count, liver and renal
functions, levels of anti-double stranded DNA (dsDNA) titer,
serum complements C3 and C4 levels were performed at study
visit. SLEDAI [25] and Systemic Lupus International Collaborat-
ing Clinics score (SLICC) [26] were evaluated during clinical
assessment. Serum level of anti-dsDNA was measured by in house
ELISA using a calibration curve generated from six standards
which were prepared with reference to the WHO international
standard serum Wo80. The interassay coefficient of variation of
the immunoassay for low and high controls was 14.7 and 6.7%,
respectively. Serum C3 and C4 levels were determined by
immunonephelometry (Immage 800; Beckman Coulter, Califor-
nia, USA). Flare is defined as increase in SLEDAI score by 3 or
more compared to the last clinical visit [27,28]. Major organ
involvement was defined as the involvement of one or more of the
following organs: the central nervous system, kidney, lung, heart
and the hematologic system (hemolytic anemia, platelet
,100,000/mL). Immunosuppressive agents included prednisolone,
hydroxychloroquine (HCQ), azathioprine (AZA), cyclophospha-
mide (CYC) (oral or IV), cyclosporin A and mycophenolate mofetil
(MMF) were prescribed for SLE patients.
Flow cytometric analysis for T, B lymphocytes, monocytes
and dendritic cells
PBMCs from SLE patients and HCs were purified by Ficoll Plus
gradient centrifugation (GE Healthcare Life Sciences, NJ, USA).
R-phycoerythrin (PE)-conjugated CD4, peridinin chlorophyll
protein (PerCP)-conjugated CD8 and allophycocyanin (APC)-
conjugated CD19 antibodies were purchased from BD Pharmin-
gen Corp. for the identification of the CD4
+ T, CD8
+ T and
CD19
+ B lymphocyte sub-populations. Peripheral blood mono-
cytes were analyzed by excluding lymphocytes using their forward-
and side-scatter properties [7].
For the analysis of DCs, fluorescein iso-thiocyanate (FITC)-
conjugated mouse anti-human major histocompatibility complex
(MHC) Class II DR monoclonal antibody was used for prior
positive gating (Thermo Fisher Scientific, NH, USA). PE-
conjugated anti-CD14 and CD16, APC-conjugated anti-immu-
noglobulin-like transcript (ILT)-3/CD85k/LIR5 (Beckman Coul-
ter Inc, CA, USA) antibody and PerCP-conjugated anti-CD33
antibody purchased from BD Biosciences Pharmingen were used
according to our previously established method [29]. The DC
population is identified as CD14 and CD16 double negative and
CD85k positive population. Myeloid DCs (mDCs) and plasmacy-
toid DCs (pDCs) were further identified by high and low CD33
expression, respectively.
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The expression of NOD2 of different immune cell types of SLE
patients and control subjects was investigated by flow cytometry
(BD FACSCalibur, BD Biosciences Corp, CA, USA) as previously
described [7]. Serum-blocked PBMCs were fixed and permeabi-
lised using Fix/Perm solution (BD Biosciences, Mississauga, ON,
Canada) for the intracellular staining of NOD2. Unconjugated
mouse anti-NOD2 antibody (Bio-legend Corp, CA, USA),
corresponding mouse IgG1, k isotypic control antibody (BD
Pharmingen Corp., San Diego, CA, USA), together with a
fluorescein iso-thiocyanate (FITC)-conjugated goat anti-mouse
IgG (H+L) secondary antibodies (Zymed Laboratories, Inc., CA,
USA), were used for intracellular staining. The expression of
NOD2 in final cell suspension with 10,000 events was assessed
using flow cytometry and the results were expressed as mean
fluorescence intensity (MFI).
Ex vivo induction of cytokines by NOD2 ligand
Aliquots of 1610
5 cells resuspended PBMCs in culture
medium RPMI1640 supplemented with 10% fetal calf serum
(Gibco Laboratories) were dispensed in each well of a 96-well
plate (Nalge Nunc International, IL, USA). The culture medium
used was free of detectable endotoxin (,0.1 EU/ml) and all other
solutions were prepared using pyrogen-free water and sterile
polypropylene plastic ware. The cells were then incubated with or
without NOD2 ligand muramyl dipeptide (MDP) (Invivogen
Corp, San Diego, CA, USA) at 0.5 mg/ml for 24 h at 37uCi na
5% CO2 atmosphere. The cell-free supernatant was harvested
and stored at 270uC for subsequent assays of cytokines and
chemokines.
Assay of the induction of human cytokines by NOD2
stimulation
The basal concentration and induction of cytokines including
interleukin (IL)-1b, tumour necrosis factor (TNF)-a, IL-6, IL-8
and IL-10 were measured simultaneously using human inflam-
matory cytokine Cytometric Bead Array (BD Pharmingen Corp.,
San Diego, CA, USA) using flow cytometry (FACSCalibur, BD
Biosciences). Supernatant samples were analyzed using a multi-
fluorescence BD FACSCalibur
TM flow cytometer with BD
CellQuest
TM software and BD
TM CBA software. The relative
percentage inductions of cytokines compared with medium
control was calculated based on the percentage difference of
induction in medium and after NOD2 ligand stimulation.
Relative induction of cytokine (%) was calculated by the
equation, (induction of cytokine by NOD2 ligand activation -
induction of cytokine of medium control)/induction of cytokine of
medium control 6100%.
Statistical analysis
Results were expressed as mean 6 standard (SD) for normally
distributed data. Non-normally distributed data were expressed as
median (interquartile range, IQR). Chi-squared tests were used
for categorical variables. For continuous variables, Student’s t-test
and Mann-Whitney U tests were used, where appropriate.
Association between the potential explanatory variables and
NOD2 expression were tested using Chi-square tests for
categorical variables and Person or Spearman correlation for
continuous variables with normal and skewed distribution,
respectively. Variables with p value ,0.05 in the univariate
analysis were entered into linear regression analysis (stepwise,
forward). Variables that were skewed were logarithmically
transformed before entering the regression analysis. All hypoth-
eses were 2-tailed, and p values ,0.05 were consider significant.
Analyses were performed using SPSS for Windows, version 13.0
(SPSS Inc., Chicago, IL, USA).
Results
Characteristics of SLE patients and control subjects
Forty-seven female Chinese SLE patients were recruited and
divided into 1 of 3 SLE groups according to the current disease
activity and the use of immunosuppressants as listed before (Group
1, 2 and 3: n=17, 13 and 17 respectively). Thirty-one age-
matched (36612 years) female healthy Chinese volunteers were
recruited as controls. Demographics and clinical characteristics
were summarized in Table 1. The mean disease duration among
the three SLE groups was similar. Group 1 had low cumulative
inflammatory burden as indicated by a significantly lower damage
index (SLICC) and a significantly lower prevalence of major organ
involvement compared to Groups 2 and 3, and a low disease
activity not requiring immunosuppressants. Current disease
activity as reflected by the SLEDAI scores were significantly
higher in Group 3 compared to Groups 1 and 2 according to the
study design, and all patients in Group 3 had a recent flare of
disease activity. Serologically, Group 3 patients had a significantly
lower level of C3 and C4, and a higher prevalence of elevated anti-
dsDNA antibody levels compared with Group 1. Clinical
manifestations at the time of study included neuropsychiatric (4/
47, 9%), nephritis (27/47, 57%), serositis (4/47, 9%), haemato-
logical (14/47, 30%) and arthritis (18/47, 38%). Cutaneous
manifestations included discoid rash (3/47, 6%), malar rash (11/
17, 23%), photosensitivity (7/47, 15%) and oral ulcers (3/47, 6%).
Group 3 patients had a significantly higher prevalence of nephritis
(17/17, 100%) and hematological involvement (9/17, 53%), as
well as a significantly higher proportion of patients who had
received MMF.
Protein expression of NOD2 in T and B lymphocytes,
monocytes and DCs
The differential protein expression of intracellular pathogen
recognition receptor NOD2 in (A) CD4+ T, (B) CD8+ T, (C)
CD19+ B, (D) Monocytes, (E) mDCs and (F) pDCs of SLE patients
and HCs by flow cytometry were shown in scatter plots as average
mean fluorescence intensity (MFI) (Figure 1).
Effects of SLE on NOD2 expression compared to healthy
controls
NOD2 expression in monocytes (Figure 1D, p=0.045) and
pDCs (Figure 1F, p=0.011) were significantly increased in SLE
patients with inactive disease who were not receiving immuno-
suppressive treatment (Group 1) when compared to HCs.
Effects of immunosuppressants on NOD2 expression in
SLE compared to healthy controls
For SLE patients who had been on immunosuppressants,
NOD2 expression was significantly decreased in mDCs (Figure 1E,
p=0.016) and pDCs (Figure 1F, p=0.018) of patients with active
disease (Group 3) when compared to HCs. Similarly, significantly
decreased NOD2 expression was observed in CD4+ T lympho-
cytes (Figure 1A, p=0.025), CD8+ T lymphocytes (Figure 1B,
p=0.004), monocytes (Figure 1D, p=0.022), mDCs (Figure 1E,
p=0.001), pDCs (Figure 1F, p=0.003) of patients with inactive
disease (Group 2) compared to HCs.
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SLE patients (n=47)
Group 1
(n=17)
Group 2
(n=13)
Group 3
(n=17)
Demographic characteristics
Sex (female/male) 17/0 13/0 17/0
Age at study, mean 6 s.d. (range), year 42615 (12–63) 44610 (26–65) 36612 (19–59)
Clinical features
SLE duration, mean 6 s.d. (range), year 965 (0–18) 867 (0–27) 866 (0–21)
SLICC 0 (0–0)
&, * 1 (0–2) 0 (0–4)
SLEDAI score 0 (0–1)
*** 0 (0–2)
## 6 (4–11)
Flare
333, no. (%) 0/17 (0%)
*** 0/17 (0%)
### 17/17 (100%)
Serological features
Serum complement C3, g/l 0.8 (0.8–1.1)
** 0.7 (0.6–1.0)
# 0.6 (0.4–0.8)
Serum complement C4, g/l 0.2 (0.2–0.3)
** 0.2 (0.2–0.3)
# 0.1 (0.1–0.2)
Elevated anti-dsDNA (.100 IU/ml), no. (%) 0/17 (0%)
&&, *** 7/13 (54%) 14/17 (82%)
Anti-dsDNA titer, IU/ml n.a. 3416239 (150–840) 3836271 (115–1000)
Number of major organ involvement, n. (%) 5/17 (29%)
&&&, ** 11/13 (85%) 17/17 (100%)
0 12/17 (71%)
&&&, ** 2/13 (15%) 0/17 (0%)
1 5/17 (29%) 7/13 (54%)
# 2/17 (12%)
$2 0/17 (0%)
&, *** 4/13 (31%)
## 15/17 (88%)
Clinical manifestation, n. (%)
Neuropsychiatric 4/47 (9%)
0/17 (0%) 1/13 (8%) 3/17 (18%)
Nephritis 27/47 (57%)
2/17 (12%)
&&, *** 8/13 (62%)
## 17/17 (100%)
Serositis 4/47 (9%)
0/17 (0%) 1/13 (%) 3/17 (18%)
Hematologic 18/47 (38%)
3/17 (18%)
* 6/13 (46%) 9/17 (53%)
Immunosuppressive therapy ever, n (%) n.a. 13/13 (100%) 17/17(100%)
Prednisolone n.a. 12/13 (92%) 16/17 (94%)
Hydroxychloroquine n.a. 10/13 (77%) 13/17 (76%)
Azathioprine n.a. 10/13 (77%) 10/17 (59%)
Cyclophosphamide (oral or IV) n.a. 7/13 (54%) 4/17 (24%)
Cyclosporin A n.a. 1/13 (8%) 2/17 (12%)
Mycophenolate mofetil n.a. 1/13 (8%)
# 7/17 (41%)
Values are median (interquartile range, IQR) unless stated otherwise; s.d., standard deviation; n.a., not applicable. SLE, systemic lupus erythematosus; Group 1) Patients
with inactive disease (SLEDAI ,4) who were never treated with immunosuppressants since the diagnosis or within the past 10 years, whichever longer; Group 2)
Patients with inactive disease (SLEDAI ,4) who had received or are currently on immunosuppressants; Group 3) Patients with active disease (SLEDAI .4) who had
received or are currently on immunosuppressants. SLEDAI, systemic lupus erythematosus disease activity index; SLICC, Systemic Lupus International Collaborating
Clinics Score;
3‘‘Never’’ refers to SLE patients never be given treatment of immunosuppressants [prednisolone, hydroxychloroquine, azathioprine, cyclophosphamide (oral or IV),
cyclosporin A and mycophenolate mofetil] since the diagnosis of SLE or within recent 10 years;
33‘‘Ever’’ refer to use of immunosuppressants since the diagnosis of SLE.
333‘‘Flare’’ is defined as increase in the SLEDAI score by 3 or more;
&p,0.05,
&&p,0.01,
&&&p,0.001, comparing between Group 1 and Group 2;
*p,0.05,
**p,0.01,
***p,0.001, comparing between Group 1 and Group 3;
#p,0.05,
##p,0.01,
###p,0.001, comparing between Group 2 and Group 3.
doi:10.1371/journal.pone.0023855.t001
Down-Regulated NOD2 in SLE
PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e23855Figure 1. Expression of intracellular NOD2 in CD4
+ T, CD8
+ T, CD19
+ B lymphocytes, monocytes, myeloid dendritic cells and
plasmacytoid dendritic cells using flow cytometry. Group 1) Patients with inactive disease (SLEDAI ,4) who were never treated with
immunosuppressants since the diagnosis or within the past 10 years, whichever longer; Group 2) Patients with inactive disease (SLEDAI ,4) who had
received or are currently on immunosuppressants; Group 3) Patients with active disease (SLEDAI .4) who had received or are currently on
immunosuppressants. The differential protein expression of intracellular pathogen recognition receptor NOD2 in (A) CD4+ T lymphocytes, (B) CD8+ T
lymphocytes, (C) CD19+ B lymphocytes, (D) Monocytes, (E) myeloid dendritic cells (F) plasmacytoid dendritic cells of SLE patients and healthy controls
by flow cytometry were shown as median (IQR) of mean fluorescence intensity (MFI) subtracting corresponding isotypic controls in scatter plots.
doi:10.1371/journal.pone.0023855.g001
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SLE
For SLE patients with inactive disease (Groups 1 and 2), the
expression of NOD2 were found to be significantly lower in CD8+
T (Figure 1B, p=0.027), monocytes (Figure 1D, p=0.002), mDCs
(Figure 1E, p=0.024), pDCs (Figure 1F, p=0.007) in the group
treated with immunosuppressants (Group 2) when compared to
the non-treated group (Group 1). Moreover, NOD2 expression
was decreased significantly in monocytes (Figure 1D, p=0.047)
and pDCs (Figure 1F, p=0.012) in SLE patients with active
disease despite on immunosuppressive treatment (Group 3)
compared with those with inactive disease who were not receiving
immunosuppressive treatment (Group 1). However, there was no
significant difference in NOD2 expression between SLE patients
on immunosuppressants with (Group 3) and without (Group 2)
active disease (Figure 1A–F) (all p.0.05).
Associations between clinical demographic variables, the
use of immunosuppressants and the expression of NOD2
Tables 2, 3 and 4 summarized the association between clinical
and treatment variables and the expression of NOD2 in the
univariate analysis (Table 2: continuous variables, Table 3 and 4:
categorical variables). There were positive correlations between
disease duration and the expression of NOD2 in CD8+ T, CD19+
B and monocytes (all p,0.01) (Table 2). Significantly increased
NOD2 expression in CD19+ B was found in patients with more
than one major organ involvement compared with those without
major organ involvement (118651 MFI vs 93631 MFI, p,0.05)
(Table 3).
With regard to the role of immunosuppressants, the expression
of NOD2 was significantly lower in CD4+ T, CD8+ T
lymphocytes, monocytes, mDCs and pDCs of SLE patients ever
treated with immunosuppressants when compared to those
without immunosuppressants (Tables 3 and 4). Prednisolone use
was associated with a significantly decreased expression of NOD2
in monocytes, mDCs and pDCs compared to the prednisolone
naı ¨ve group (Table 4). Significantly decreased expression of
NOD2 was found in patients treated with HCQ and AZA in
pDCs compared with those who never been treated with HCQ
and AZA (p,0.01) (Table 4). NOD2 expression in the monocytes
was significantly lower in patients treated with CYC compared to
the CYC naı ¨ve group (p,0.05). No differences were found in
NOD2 expression between these patients who had or had not
been treated with cyclosporin A or MMF (all p.0.05).
Risk factors associated with NOD2 expression in SLE
In order to address whether the clinical characteristics; use of
immunosuppressive therapy ever; current and cumulative dose of
immunosuppressants and are independent predictors affecting the
expression of NOD2, all of the potential explanatory variables
with a p-value less than 0.05 identified in the univariate analysis
[including disease duration, major organ involvement ($1),
current and cumulative dose of AZA, immunosuppressive therapy
(prednisolone, HCQ, AZA and CYC) ever] were analyzed using
linear regression analysis (Table 5). Ever use of immunosuppres-
sive therapy was as an independent explanatory variable for
downregulating the expression of NOD2 in CD8+ T [Adjusted
coefficient (95%): 234.765 (266.508 to 23.021); Adjusted R
2:
0.191], monocytes [Adjusted coefficient (95%): 292.110
(2152.542 to 231.678); Adjusted R
2: 0.163], mDCs [Adjusted
coefficient (95%): 296.098 (2173.200 to 218.995); Adjusted R
2:
0.108] and pDCs [Adjusted coefficient (95%): 2132.403
(2203.118 to 261.689); Adjusted R
2: 0.232] (all p,0.05). On
the other hand, a longer disease duration was an independent risk
factor for upregulating the expression of NOD2 in CD8+ T
[Adjusted coefficient (95%): 3.152 (0.703 to 5.601); Adjusted R
2:
0.121], CD19+ B [Adjusted coefficient (95%): 2.768 (0.836 to
4.700); Adjusted R
2: 0.137] and monocytes [Adjusted coefficient
(95%): 6.028 (1.366 to 10.691); Adjusted R
2: 0.258] (all p,0.05)
(Table 5).
Effects of NOD2 agonist (MDP) on the induction of
cytokines from PBMC
In order to examine whether the NOD2 expression was
functional, we exposed PBMC to specific NOD2 ligand MDP
and investigated the ex vivo induction of cytokines using flow
cytometry. As shown in Table 6, the basal productions of cytokines
(IL-6, IL-8 and IL-10) were significantly increased in Group 1 and
Group 3 compared with HCs (all p,0.05). Basal concentration of
IL-10 was significantly higher in Group 2 compared to HCs, albeit
significantly lower than Group 1.
As shown in Table 6, the relative induction (%) of cytokines (IL-
1b and IL-10) upon NOD2 ligand (MDP) stimulation from PBMC
was significantly increased Group 1 compared with HCs (p,0.05).
The relative induction (%) of IL-1b in response to MDP was
increased in Group 3 compared to HCs (p,0.05). An observable
diminished relative induction (%) of IL-10 was observed in Group
2 compared to Group 1 and HCs (p,0.05). No significant
differences were observed for the relative induction (%) of TNF-a,
IL-6 and IL-8 from PBMCs upon the activation by NOD2 ligand
between the four groups (all p.0.05).
Discussion
Bacterial (Staphylococcus aureus, Streptococcal pneumonia, Escherichia
coli and Pseudomonas aeruginosa) [30] and viral infections (cytomeg-
alovirus, Epstein-Barr virus, parvovirus B19 and papillomavirus)
have been suggested to be pathogenic triggers for the development
or exacerbation of SLE either through persistent infection or the
presence of remnants of pathogens [31,32]. Recognition of these
microorganisms is mediated, at least in part, by TLRs, and TLR-
induced pathways are responsible for the induction of proin-
flammatory mediators [33,34]. In addition to TLRs, Pseudomonas
aeruginosa and Streptococcal pneumonia can also be recognized by
NOD1 and NOD2, respectively [35]. Activation of NOD1 and
NOD2 has been shown to stimulate the cytokine production and
neutrophil recruitment [36], and mediate TLR-induced cytokine
production [5,15], respectively. Apart from the putative
link between the genetic variants of NOD2 and SLE
[18,19,20,21,22,23], little is known about the expression and
function of NOD2 in SLE.
NOD2 is expressed in intestinal epithelial paneth cells,
lymphocytes and myeloid cells such as monocytes, macrophages
and DCs that are in direct contact with microbial organisms,
whereas NOD1 is expressed in non-myeloid cells such as epithelial
cells and fibroblasts [37,38]. When the NOD2 gene functions
normally, it codes for a cytosolic innate receptor which is able to
sense PGNs from Gram-positive and negative bacteria and to
trigger signaling pathway mediated pro-inflammatory and anti-
bacterial response [39]. Van et al. demonstrated that the T helper
(Th)17-mediated, antibacterial immunity in humans is orchestrat-
ed by DCs upon sensing of bacterial NOD2-ligand MDP [40]. In
patients with chronic inflammatory diseases, aberrant expression
and function of NOD2 has been reported mainly in inflammatory
bowel disease and other inflammatory disorders [6,16,17]. Recent
studies have demonstrated that the mRNA[16] and protein[6] of
NOD2 were expressed in synovial tissue samples from RA
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expression of proinflammatory cytokines and matrix-degrading
enzymes via p38 mitogen-activated protein kinases (MAPK) and
NF-kB signaling pathways [6]. In agreement with previous studies,
we observed a significantly higher expression of NOD2 in
monocytes and pDCs in immunosuppressive therapy naı ¨ve SLE
patients (Group 1) compared with HCs. Inflammatory burden as
reflected by the disease duration played a role as an independent
explanatory variable for upregulating the expression of NOD2 in
monocytes.
Cytokines play an important and diverse role in the pathogen-
esis of SLE, and their balance determines disease activity [41,42].
Proinflammatory cytokines such as IL-1b, IL-6, IL-8 and TNF-a
are found to possess potent stimulatory effects on T, B
lymphocytes, natural killer (NK) cells, and neutrophils in
increasing the biosynthesis of prostaglandins and acute-phase
proteins [43], whereas Th2 cells produce anti-inflammatory
cytokine, IL-10, to modulate immunity to extracellular parasites
[44]. Elevated basal production of cytokines including TNF-a, IL-
6, IL-8 and IL-10, both in serum and culture, has been reported in
SLE patients compared with healthy controls [45,46,47]. Our
results concurred with previous studies showing that the basal
production of cytokines (IL-6, IL-8 and IL-10) was significantly
increased in immunosuppressive naı ¨ve patients (Group 1) and
patients with active disease despite immunosuppressive therapy
(Group 3) compared with HCs, implying that the imbalance
between proinflammatory (IL-6 and IL-8) and anti-inflammatory
(IL-10) cytokines may trigger the inflammatory process in SLE.
In order to confirm whether the NOD2 protein was functional,
NOD2 agonist (MDP)-stimulated production of pro- and anti-
inflammatory cytokines from SLE patients and HCs were
measured. Production of IL-1b has been reported upon stimula-
tion with MDP [48,49], while IL-1b blockade profoundly inhibits
MDP-induced cytokine production in macrophage, demonstrating
a key role of IL-1b in NOD2-mediated inflammation[49].
Consistent to the previous finding, upon stimulation with NOD2
agonist, our data showed an observable increased relative
induction (%) of IL-1b upon MDP stimulation in SLE patients
(Groups 1 and 3) compared to controls. IL-1 is one of the most
pleiotropic pro-inflammatory and immunostimulatory cytokines.
Table 2. Univariate analysis: Person or Spearman’s correlation between the expression of NOD2 and clinical demographic
variables in SLE patients (continuous variables).
NOD2 expression
CD4+ T
lymphocytes
CD8+ T
lymphocytes CD19+ B Monocytes mDC pDC
nr nr nr nr nr nr
Clinical characteristics
SLE duration, year 47 0.287 47 0.423
** 47 0.486
** 47 0.466
** 45 0.255 45 0.132
SLEDAI score 47 0.184 47 0.115 47 0.265 47 0.221 45 0.245 45 0.319
Serum C3, g/l 47 0.067 47 0.067 47 0.115 47 0.201 45 0.046 45 0.168
Serum C4, g/l 47 0.077 47 0.058 47 0.071 47 0.108 45 20.019 45 0.095
Anti-dsDNA titer, IU/ml 21 0.221 21 20.131 21 20.400 21 20.378 20 20.031 20 20.076
Immunosuppressive therapy
Prednisolone
Current dose, mg 29 20.125 29 20.047 29 20.043 29 20.019 27 0.206 27 20.095
Cumulative dose, g 29 0.018 29 20.096 29 0.156 29 20.105 27 20.017 27 20.015
Hydroxychloroquine
Current dose, mg 19 0.223 19 0.280 19 0.109 19 0.351 18 0.586 18 0.177
Cumulative dose, g 23 0.320 23 0.008 23 0.045 23 0.058 22 0.203 22 0.001
Azathioprine
Current dose, mg 7 20.532 7 20.808
* 7 20.315 7 20.611 6 20.440 6 20.371
Cumulative dose, g 20 20.147 20 20.087 20 20.138 20 20.045 18 20.560
* 18 0.041
Cyclophosphamide (oral or IV)
Current dose, mg 6 20.949 6 20.633 6 20.633 0 20.633 6 20.791 6 20.649
Cumulative dose, g 11 0.529 11 0.242 11 0.295 11 20.258 9 0.333 9 20.171
Cyclosporin A
Current dose, mg 1 n.a. 1 n.a. 1 n.a. 1 n.a. 1 n.a. 1 n.a.
Cumulative dose, g 3 n.a. 3 n.a. 3 n.a. n.a. 3 n.a. 3 n.a.
Mycophenolate mofetil
Current dose, mg 0 n.a. 0 n.a. 0 n.a. 0 n.a. 0 n.a. 0 n.a.
Cumulative dose, g 8 20.667 8 0.238 8 0.143 8 20.489 8 20.119 8 20.289
mDC, myeloid dendritic cells; pDC, plasmacytoid dendritic cells; r = Person or Spearman’s correlation coefficient;
*p,0.05,
**p,0.01.
doi:10.1371/journal.pone.0023855.t002
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pathogenicity of various autoimmune inflammatory diseases,
including SLE. In an experimental model, mice deficient in IL-
1b developed lower levels of anti-dsDNA antibodies, milder
disease manifestations and reduced cytokine cascade that is the
characteristics of overt experimental SLE [50]. Spontaneous
release of IL-1 from SLE monocytes has been reported as
increased in many, but not all studies [41,51,52]. Therefore, the
proinflammatory state resulting from the increased expression of
NOD2 in the immunosuppressive naive SLE patients, together
with previous reports regarding the increase in the expression of
TLRs [7], underscores the importance of the activation of innate
immune mechanisms in SLE. Data from our group as well as
others provided evidence which may suggest that certain
bacterial/viral components from an initial infection may lead to
the activation of innate immune receptors, which provokes an
inflammatory reaction and contribute towards the initiation of the
pathogenic process in SLE. Further functional, signaling and
genetic work will need to be performed to investigate whether
higher level of cytokines are a result of NOD2-mediated flare in
SLE, or whether the pro- or anti-inflammatory cytokines play a
role in initiating and perpatuating the NOD2-mediated inflam-
matory process.
We have demonstrated that immunosuppressive therapy may
play a role as an independent explanatory variable associated with
the decreased expressions of NOD2 in CD8+ T, monocytes,
mDCs and pDCs. Emerging evidence has reported that derivatives
and small molecule analogues of chloroquine and quinacrine
suppress the over-activation of immune response.[53,54] These
anti-malarial agents[55] (chloroquine, HCQ and quinacrine) used
for the treatment of immune-mediated inflammatory disorders
(IMID) such as SLE, are antagonists of TLR-9 and to a lesser
extent, TLR-7 and -8 [54]. Similarly, high dose glucocorticoster-
oids could also reduce the in vivo TLR responses by 70–90% [56].
The effects of TLR antagonists on NOD2 expression in SLE
patients have not been well elucidated, nonetheless, a synergistic
effect of NODs and TLRs has been reported in other diseases
[6,57,58]. Whether immunosuppressive therapy may have a direct
effect on downregulating the expression of NOD2 in SLE patients,
or indirectly through the interaction between NOD2 and TLRs in
SLE patients need further investigation.
In the present study, the basal concentration of IL-10 was
significantly lower in patients with inactive disease receiving
immunosuppressive therapy compared to those without immuno-
suppressants. Furthermore, the use of immunosuppressant was
associated with an observable diminished relative induction (%) of
IL-10 upon stimulaiton with MDP in SLE patients with inactive
disease. IL-10 is an important immunoregulatory cytokine that
inhibits T cell function by suppressing the expression of
proinflammatory cytokines such as TNF-a, IL-1, IL-6, IL-8, and
IL-12 [59–60]. It also inhibits antigen presenting cells by
downregulating major histocompatibility complex class II
(MHC-II) and B7 expression [61]. In addition to these inhibitory
actions, IL-10 promotes B-cell-mediated functions, enhancing
Table 3. Univariate analysis: the relationship between clinical characteristics, the use of drugs ever and the expression of NOD2 in
SLE patients (categorical variables).
NOD2 expression
CD4+ T lymphocytes CD8+ T lymphocytes CD19+ B lymphocytes
Yes No Yes No Yes No
nnnnn n
Clinical characteristics
Flare
3 17 100646 30 109654 17 110653 30 112660 17 109652 30 110640
Elevated anti-dsDNA
(.100 IU/ml)
21 93644 26 116655 21 100653 26 121660 21 102649 26 116640
Major organ involvement $1 32 103641 15 111669 32 109648 15 111669 32 118651* 15 93631
Clinical manifestations
Neuropsychiatric 4 110686 43 105648 4 113689 43 111656 4 112676 43 109641
Nephritis 27 99641 20 114662 27 104649 20 122667 27 109646 20 110643
Serositis 4 136667 43 103649 4 134673 43 110656 4 147657 43 106642
Hematologic 18 114647 29 101654 18 119650 29 107662 18 126648 29 99639
Immunosuppressive therapy
ever
33
30 93643
* 17 128658 30 98651
* 17 136661 30 103648 17 122 634
Prednisolone 29 95641 18 122661 29 100650 18 130660 29 106647 18 116640
Hydroxychloroquine 23 100646 24 111656 23 105655 24 118660 23 110656 24 109635
Azathioprine 20 103643 27 108657 20 105653 27 117661 20 112643 27 108646
Cyclophosphamide
(oral or IV)
11 95635 36 109655 11 95640 36 117661 11 104632 36 110647
Cyclosporin A 3 75610 44 108652 3 96619 44 113659 3 98619 44 110645
Mycophenolate mofetil 8 96638 39 107653 8 121649 39 110659 8 113651 39 109643
3‘‘Flare’’ is defined as increase in the SLEDAI score by 3 or more;
33‘‘Ever’’ refers to use of immunosuppressants [prednisolone, hydroxychloroquine, azathioprine, cyclophosphamide (oral or IV), cyclosporin A and mycophenolate
mofetil] since the diagnosis of SLE;
*p,0.05.
doi:10.1371/journal.pone.0023855.t003
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SLE patients (categorical variables).
NOD2 expression
Monocytes Myeloid dendritic cells Plasmacytoid dendritic cells
Yes No Yes No Yes No
n nnnnn
Clinical characteristics
Flare
3 17 2496114 30 2746115 17 2466150 28 2496122 17 2076132 28 2656126
Elevated anti-dsDNA
(.100 IU/ml)
21 2346117 26 2906107 20 2266147 25 2656118 20 2106140 25 2716120
Major organ involvement
$1
32 2416104 15 3166121 30 2406146 14 264698 30 2326137 14 2896117
Clinical manifestations
Neuropsychiatric 4 2286155 43 1686111 4 2216184 41 2506128 4 2396140 41 2436131
Nephritis 27 2376106 20 3026117 25 2326141 20 2696104 25 2226135 20 2796119
Serositis 4 2906130 43 2636114 4 3336219 41 2396121 4 2096169 41 2466128
Hematologic 18 2946118 29 2476110 18 2806161 27 2266105 18 2526154 27 2376114
Immunosuppressive
therapy ever
33
30 2296104
** 17 3296105 28 2116143
*** 17 308683 28 1926130
*** 17 325679
Prednisolone 29 2326105
* 18 3186114 27 2126146
** 18 301686 27 1936133
*** 18 318683
Hydroxychloroquine 23 2476111 24 117624 22 2306154 23 2646106 22 2016143
** 23 2836104
Azathioprine 20 231699 27 2916120 18 2236156 27 2646113 18 1996133
* 27 2726122
Cyclophosphamide (oral
or IV)
11 198677
* 36 2856177 92 0 1 6102 36 2596137 9 1866100 36 2576134
Cyclosporin A 3 185658 44 2706115 3 169650 42 2536134 3 125647 42 2516130
Mycophenolate mofetil 8 2726133 39 2646112 8 2696129 37 2436134 8 2526142 37 2416130
3‘‘Flare’’ is defined as increase in the SLEDAI score by 3 or more;
33‘‘Ever’’ refers to the use of immunosuppressants [prednisolone, hydroxychloroquine, azathioprine, cyclophosphamide (oral or IV), cyclosporin A and mycophenolate
mofetil) since the diagnosis of SLE;
*p,0.05,
**p,0.01,
***p,0.001.
doi:10.1371/journal.pone.0023855.t004
Table 5. Independent risk factors associated with the expression of NOD2 in T and B lymphocytes, monocytes and DCs of SLE
patients.
Linear regression (stepwise selection) analysis
n Risk factors Adjusted coefficient (95%) P-value Adjusted R
2
CD8+ T lymphocytes 47 SLE duration, year 3.152 (0.703 to 5.601) 0.013 0.121
47 Immunosuppressive therapy ever
33 234.765 (266.508 to 23.021) 0.033 0.191
CD19+ B lymphocytes 47 SLE duration, year 2.768 (0.836 to 4.700) 0.006 0.137
NOD2
expression
Monocytes 47 Immunosuppressive therapy ever 292.110 (2152.542 to
231.678)
0.004 0.163
47 SLE duration, year 6.028 (1.366 to
10.691)
0.012 0.258
Myeloid dendritic cells 45 Immunosuppressive therapy ever 296.098 (2173.200 to
218.995)
0.016 0.108
Plasmacytoid dendritic cells 45 Immunosuppressive therapy ever 2132.403 (2203.118 to
261.689)
0.000 0.232
33‘‘Ever’’ refers to the use of immunosuppressants [prednisolone, hydroxychloroquine, azathioprine, cyclophosphamide (oral or IV), cyclosporin A and mycophenolate
mofetil] since the diagnosis of SLE.
doi:10.1371/journal.pone.0023855.t005
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[62]. Hence, increased production of IL-10 could thus explain B
cell hyperactivity and autoantibody production, two main features
of the immune dysregulation in SLE. In fact, elevated levels of this
molecule have been currently reported in SLE patients, frequently
associated with the indicators of disease activity [63,64]. NOD2
mutation in CD patients results in the suppression of the
production of IL-10 [65]. Here, we hypothesize that part of the
beneficial effect of immunosuppressive therapy may be mediated
by the downregulation of NOD2, resulting in a redution of the
basal and MDP induced production of IL-10 in SLE patients.
Further studies exploring the mechanisms of how immunosup-
pressant regulate NOD2 expresssion and function in SLE will be
warranted.
Failure to induce an effective cellular immune response because
of inefficient activation of innate immunity and ineffective priming
of the adaptive immune response in patients with lupus may lead
to an increased prevalence as well as persistence of any infection.
In patients with CD, dysfunctional NOD2 variants in the intestinal
epithelial and phagocytic cells results in the deficiencies in
epithelial-barrier function which subsequently lead to increased
bacterial invasion and inflammation at intestinal sites. Other study
has demonstrated that NOD2-deficient mice infected orally with
L. monocytogenes had a significantly greater bacterial burden in liver
and spleen than wild-type mice [66]. NOD2-deficient mice have
impaired resistance to mycobacterium tuberculosis infection
through defective innate and adaptive immunity [67]. Our group
also reported a higher prevalence of mycobacterial tuberculosis
infection in patients with SLE [68], and there are several reports
suggesting that mycobacterium tuberculosis infection precipitates
SLE in patients from endemic areas [69]. Whether decreased
NOD2 expression may contribute towards the induction and
reactivation of chronic inflammation by mycobacterial infection in
patients with SLE deserves further study. On the other hand, apart
from the direct immuno-modulating effects, the use of immuno-
suppressive agents may increase the risk of infections in SLE
patients. Viral infections have been reported to down-regulate
innate immune receptors in the host resulting in persistent
infection, e.g. human papillomavirus virus (HPV) type 16 infection
has been reported to down-regulate TLR 9 pathway promoting
persistent infection in the host [70]. Similarly, chronic hepatitis C
infection leads to a decrease in expression and functional
Table 6. Ex vivo basal production and relative induction of cytokines from NOD2 ligand activated PBMC in various groups.
Cytokines n
Basal production (IQR)
(pg/10
5 PBMCs)
(Medium)
Relative induction (%) (IQR)
(pg/10
5 PBMCs)
(MDP)
Group 1 16 3.7 (2.9 to 4.4) 212.0 (135.2 to 296.7)
D
IL-1b SLE Group 2 9 3.5 (3.3 to 3.7) 173.4 (156.8 to 244.1)
Group 3 11 3.3 (3.1 to 3.7) 217.2 (137.8 to 240.9)
1
Healthy control 23 3.5 (3.1 to 4.1) 153.9 (106.6 to 192.6)
Group 1 16 3.0 (2.6 to 3.7) 24.2 (21.0 to 33.8)
TNF-a SLE Group 2 9 2.6 (2.2 to 3.1) 19.6 (12.2 to 30.6)
Group 3 11 2.9 (2.3 to 3.7) 23.5 (19.1 to 32.1)
Healthy control 23 2.6 (2.0 to 3.2) 19.4 (16.9 to 25.2)
Group 1 16 12.2 (7.5 to 15.8)
D 18.9 (12.8 to 33.5)
IL-6 SLE Group 2 9 10.8 (8.0 to 13.7) 12.1 (5.6 to 20.3)
Group 3 11 11.3 (9.1 to 16.4)
11 23.3 (19.9 to 44.3)
Healthy control 23 8.1 (5.3 to 10.8) 18.3 (14.7 to 19.6)
Group 1 16 929.8 (463 to 1263)
D 258.1 (216.9 to 298.5)
IL-8 SLE Group 2 9 608.2 (407.9 to 809.7) 217.2 (137.8 to 240.9)
Group 3 11 727.2 (388.9 to 729.8)
1 212.0 (135.2 to 296.7)
Healthy control 23 552.8 (388.9 to 729.8) 192.4 (117.1 to 219.3)
Group 1 16 6.8 (4.3 to 14.0)
&, DDD 57.4 (38.9 to 81.1)
&&, D
IL-10 SLE Group 2 9 4.8 (3.8 to 5.3)
WW 20.9 (14.4 to 38.5)
W
Group 3 11 5.2 (5.0 to 5.6)
11 40.5 (27.0 to 59.1)
Healthy control 23 2.4 (2.3 to 2.8) 33.6 (19.4 to 46.8)
Culture supernatant was obtained from PBMCs cultured with medium or NOD2 ligand (Muramyl dipeptide, MDP) for 24 hours. The basal production (pg/ml) and relative
induction (%) of cytokines (IL-1b,T N F - a, IL-6, IL-8 and IL-10) by PBMCs were analyzed by flow cytometry. Numerical data are expressed as median (interquartile range,
IQR). Group 1) Patients with inactive disease (SLEDAI ,4) who were never treated with immunosuppressants since the diagnosis or within the past 10 years, whichever
longer; Group 2) Patients with inactive disease (SLEDAI ,4) who had received or are currently on immunosuppressants; Group 3) Patients with active disease (SLEDAI
.4) who had received or are currently on immunosuppressants.
&p,0.05, comparing between Group 1 and Group 2;
Dp,0.05,
DDDp,0.001, comparing between Group 1 with healthy control subjects;
Wp,0.05,
WWp,0.01, comparing between Group 2 with healthy control subjects;
1p,0.05,
11p,0.01 comparing between Group 3 with healthy control subjects.
doi:10.1371/journal.pone.0023855.t006
Down-Regulated NOD2 in SLE
PLoS ONE | www.plosone.org 10 August 2011 | Volume 6 | Issue 8 | e23855impairment of TLR2 [71]. Whether bacteria could also make use
of this immune evasion strategy in order to escape NOD2
recognition in patients with SLE would deserve further studies.
The main limitation of this study is that we only studied the
function of NOD2 in the PBMCs. Further studies of the
differential function of NOD in different immune cell types,
detailed cellular regulatory mechanisms of NOD2 activation and
the interaction among NOD2, TLRs and the effects of the pro-
and anti-inflammatory cytokines in SLE would be worth studying.
Although our findings have speculated that the immunosuppres-
sive therapy may be as important factor in down-regulating the
expression of NOD2, we did not explore the drug effect on
different cell types both in vivo and in vitro. It would be of interest to
further explore the mechanism in regulating NOD2 expression
and function by immunosuppressive agents including predniso-
lone, TLR antagonists and other immunosuppressive therapies in
SLE. Furthermore, a future prospective study with a larger sample
size followed for a longer period of time is warranted to study the
risk factors affecting the expression of NOD2 in SLE patients.
In conclusion, exposure to bacterial conserved molecular
pattern may increase the expression of NOD2 in the monocytes
of immunosuppressant naı ¨ve patients, which can subsequently lead
to aberrant activation of PBMCs, resulting in the production of
proinflammatory cytokines, implicating the innate immune
response for extracellular pathogens in the immunopathological
mechanisms in SLE. On the other hand, immunosuppressive
therapies may downregulate the NOD2 expression in CD8+ T
lymphocytes, monocytes, mDCs and pDCs in SLE patients which
subsequently reduce IL-10 production, contributing towards the
regulation of immunopathological mechanisms of SLE, at the
expense of increasing the risk of concurrent bacterial infection.
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